- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03873428
Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES (EstroTEPCompar)
Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of Positron Emission Tomography (PET) With 16α- [18F] -Fluoro-17β-estradiol (FES).
Breast cancer is a major public health issue despite therapeutic advances, it is the first cause of death cancer of women in Europe.
Several treatments may be proposed depending on the general condition of the patient, the characteristics of the initial tumor and the stage of the disease. The different treatments in metastatic relapse of hormone receptor-positive breast cancer are systemic treatments, such as hormone therapy, chemotherapy, targeted therapies, and possible supportive care, but also in some cases local treatments such as surgery and radiotherapy.
Comparative analysis of primary mammary tumors and their metastases has demonstrated the essential role of tumor heterogeneity, both in time and space, in the progression of the disease and the occurrence of resistance to treatments. Taking into account this intratumoral heterogeneity represents a major axis of improvement in the management of patients with breast cancer.
The use of innovative radiotracers such as 16α- [18F] -fluoro-17β-estradiol (FES) may allow in the future to better evaluate this tumor heterogeneity in patients with metastatic breast cancer through non-metastatic characterization. invasive different lesions. It will be possible to propose to each patient a more personalized care with possibly the administration, in addition to the systemic treatment, of a local treatment adapted to the characteristics of some secondary lesions likely to respond less well to the systemic treatment.
In this pilot study, the investigators would like to estimate the number of patients and the number of metastatic sites affected by tumor heterogeneity of estrogen receptor expression, which could benefit from specific management.
This study will concern a population of patients with first metastatic recurrence of hormone receptor-positive breast cancer initially, with at least one metastasis, who are candidates for treatment with hormone therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective of this pilot study is to determine the unconformity rates for estrogen receptor expression in different metastatic lesions in patients with first metastatic recurrence of breast cancer initially expressing estrogen receptors.
Secondary objectives are:
- To study the influence of the FES PET could have for possible modifications of therapeutic management in these patients.
- Determine the rate of patients with additional positive FES lesions but without positive FDG lesions.
- Evaluate the response to chemotherapy at 3 months after using FDG-PET in clinical routine.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Claire Tabouret-Viaud, MD
- Phone Number: + 33 3 80 73 75 22
- Email: ctabouret@cgfl.fr
Study Contact Backup
- Name: Emilie REDERSTORFF, PhD
- Phone Number: 34 61 +33(0)3 80 73 75 00
- Email: ERederstorff@cgfl.fr
Study Locations
-
-
-
Dijon, France, 21079
- Not yet recruiting
- CGFL
-
Contact:
- Claire Tabouret-Viaud, MD
- Phone Number: 33 3 80 73 75 22
- Email: ctabouret@cgfl.fr
-
Contact:
- Emilie REDERSTORFF
- Phone Number: 33 3 45 34 81 16
- Email: erederstorff@cgfl.fr
-
-
Bourgogne
-
Dijon, Bourgogne, France, 21000
- Recruiting
- Centre Georges-François Leclerc
-
Contact:
- Jean-Louis ALBERINI, Pr
- Phone Number: §33 03 80 73 75 22
- Email: JLAlberini@cgfl.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ECOG score (Eastern Cooperative Oncology Group) ≤ 2.
- Stage IV breast cancer (AJCC TNM).
- Primitive tumor expressing RO (> 10%).
- Patient candidate for hormone therapy treatment targeting estrogen receptors as a first-line treatment in a context of first metastatic recurrence.
- No overexpression of HER2 in the tumor.
- Lack of previous treatment for metastatic disease
- Metastatic status confirmed by 18F-FDG PET / CT performed in the month prior to inclusion
- Life expectancy estimated at more than 3 months.
- Patient able to understand and give informed informed consent for participation in the study.
- Patient affiliated with the social security scheme or equivalent.
Exclusion Criteria:
- Triple negative breast cancer
- Overexpression HER2 +++
- Metastatic involvement exclusively in the liver
- Unable to lie down or maintain the position during the PET / CT scan
- Uncontrolled intercurrent pathology that is life-threatening in the short term
- Uncontrolled diabetes
- History of an allergic reaction attributed to a chemical or biological compound related to FDG or FES
- Psychiatric impairment or social conditions that would limit patient availability and compliance at different stages of the study.
- Pregnant woman (mandatory pregnancy test at baseline) or who is breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: FES PET
1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
|
FES injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estrogen Receptor Gene Expression
Time Frame: at the inclusion
|
number of FDG+ / FES- lesions compared to the number of FDG+ / FES+ lesions
|
at the inclusion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EstroTEP COMPARE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on FES TEP in Detection of Estrogen Receptors
-
Maastricht University Medical CenterCompletedDistribution of Nutrient Receptors Studied in Intestinal Tissue Obtained Via Endoscopy
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Etablissement... and other collaboratorsRecruitingThe Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy VolunteersFrance
-
Rutgers, The State University of New JerseyMonell Chemical Senses CenterCompletedTreatment of Sweet Taste Receptors Without or With an Oral Rinse of Ibuprofen Solution in Healthy Participants | Treatment of Sweet Taste Receptors Without or With an Oral Rinse of Naproxen Solution in Healthy ParticipantsUnited States
-
Johannes Gutenberg University MainzUnknownFocus of the Study is to Evaluate a New Developed Deep-learning Computer-aided Detection System in Combination With LCI for Colorectal Polyp DetectionGermany
-
Sohag UniversityRecruitingDetection of Type VI Secretion System in K.Pneumoniae | Detection of Relation to Ab Resistance, BiofilmEgypt
-
Assiut UniversityCompletedDetection of Different Prognostic Factors and Their Relation With the Outcome | Using New Protocol to Prove the Role of N-acetyl Cysteine and Adequate Supportive Measures in Aluminum Phosphide Poisoning
-
Tonix Pharmaceuticals, Inc.Premier Research Group plcActive, not recruitingDetection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2United States
-
Hospital St. Joseph, Marseille, FranceWithdrawnFibrillation, Atrial | To Evaluate the Intraoperative Efficiency of the AIFIB Software in the Detection of Atrial Fibrillation Driver During an Ablation ProcedureFrance, Netherlands
-
Assiut UniversityNot yet recruitingFinding New Biomarkers That Could be Evaluated in Patients With Prostate Cancer and Clarify Their Role in Early Detection of Prostate CancerEgypt
-
Assiut UniversityUnknownDetection of PCM1-JAK2 Fusion Gene by FISH in the Two Types of t-MDS/AML and Relationship Between PCM1-JAK2 Fusion Gene and Cumulative Dose, Dose Intensity
Clinical Trials on FES PET
-
University Medical Center GroningenCompletedEpithelial Ovarian CancerNetherlands
-
Peking Union Medical College HospitalRecruiting
-
University of UtahRecruitingEstrogen Receptor Positive Breast CancerUnited States
-
University of UtahRecruitingInvasive Lobular Breast CarcinomaUnited States
-
University Medical Center GroningenTerminatedPostmenopausal | Psychiatric/Mood Disorder | Patient | Estrogen Receptor Levels | PremenopausalNetherlands
-
Hoag Memorial Hospital PresbyterianActive, not recruiting
-
University Medical Center GroningenBOOG Study Center; Dutch Cancer SocietyRecruiting
-
Radboud University Medical CenterUniversity Medical Center Groningen; Haukeland University Hospital; Academisch...Unknown
-
Memorial Sloan Kettering Cancer CenterCompleted
-
First Affiliated Hospital Xi'an Jiaotong UniversityUnknownEstrogen Receptor-positive Breast Cancer | FulvestrantChina